FDA tightens rules on where your GLP-1 actually comes from

On Monday, August 31, 2026, the FDA opened a public comment period tied to how compounding pharmacies register and what fees they pay under the Federal Food, Drug, and Cosmetic Act. This matters if you have relied on a compounded version of a GLP-1 medication, whether for cost reasons or because a brand-name product was hard to find. Registration and fee rules shape which pharmacies can legally operate as outsourcing facilities. That, in turn, affects what is available to you and at what price.

The FDA is asking for input on registration requirements and associated fees for outsourcing facilities that compound human drugs, which includes some pharmacies producing compounded GLP-1 products. This is a formal step in the rulemaking process, meaning the agency wants comment before it finalizes how these facilities register and what they owe. If the rules tighten registration standards or raise fees, smaller compounding pharmacies may find it harder to stay in business, which could reduce the number of compounded options on the market. On the other hand, clearer registration rules may help the FDA track which facilities are operating and hold them to consistent standards. The comment period gives pharmacies, patients, and other stakeholders a chance to weigh in before any changes take effect.

This is a proposed collection of information, not a final rule, so nothing changes for you immediately. If you currently use a compounded GLP-1 product, it is reasonable to keep an eye on how this comment period develops, since the outcome could affect which pharmacies remain available to you and what they charge. I would suggest checking in periodically with your pharmacy or prescriber about the source of your medication, particularly if you notice changes in availability or price over the coming months.

By Amanda Bonello